Encapsulated transgene cells attenuate hypertension, cardiac hypertrophy and enhance renal function in Goldblatt hypertensive rats

Journal of Gene Medicine

Volumn 6, Issue 7, 2004, Pages 786-797

  Chen, Li Guo ^a   Wang, Zheng Rong ^a   Wan, Chao Min ^b   Chao, Lee ^c   Chao, Julie ^c   Xing, Hao Yang ^a  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Atrial natriuretic peptide; Cell therapy; Encapsulated gene transfected cells; Gene therapy; Hypertension; Polycaprolactone

Indexed keywords

ATRIAL NATRIURETIC FACTOR; CYCLIC GMP; POLYCAPROLACTONE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD PRESSURE MEASUREMENT; CELL BASED GENE THERAPY; CELL ENCAPSULATION; CELL ISOLATION; CHO CELL; CONTROLLED STUDY; GENE DELIVERY SYSTEM; GENE TARGETING; GENETIC TRANSFECTION; GLOMERULUS FILTRATION RATE; HEART VENTRICLE HYPERTROPHY; HYPERTENSION; IMMUNOCYTOCHEMISTRY; IMMUNOREACTIVITY; KIDNEY BLOOD FLOW; KIDNEY FUNCTION TEST; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOIMMUNOASSAY; RAT; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; TRANSGENE; URINALYSIS; URINARY EXCRETION;

ANIMALS; ATRIAL NATRIURETIC FACTOR; BLOOD PRESSURE; CARDIOMEGALY; CHO CELLS; CRICETINAE; HYPERTENSION; KIDNEY; KIDNEY FUNCTION TESTS; MALE; MICROSCOPY, CONFOCAL; MYOCARDIUM; RATS; RATS, WISTAR; TRANSFECTION; TRANSGENES;

CRICETINAE; CRICETULUS GRISEUS; CUCUMBER MOSAIC VIRUS;

EID: 13644256236     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.563     Document Type: Article

References (32)

1. de Bold AJ. Atrial natriuretic factor: a hormone produced by the heart. Science 1985; 230: 767-770.
2. de Bold AJ, Borenstein HB, Veress AT, Sonnenberg H. A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats. Life Sci 1981; 28: 89-94.
3. Brenner BM, Ballermann BJ, Gunning ME, Zeidel ML. Diverse biological actions of atrial natriuretic peptide. Physiol Rev 1990; 70: 665-669.
4. Ruskoaho H. Atrial natriuretic peptide: synthesis, release, and metabolism. Pharmacol Rev 1992; 44: 479-602.
5. Lin KF, Chao J, Chao L. Atrial natriuretic peptide gene delivery attenuates hypertension, cardiac hypertrophy, and renal injury in salt sensitive rats. Hum Gene Ther 1998; 9: 1429-1438.
6. Murakami H, Yayama K, Chao J, Chao L. Atrial natriuretic peptide gene delivery attenuates gentamycin-induced nephrotoxicity in rats. Nephrol Dial Transplant 1999; 14: 1376-1384.
7. Ferber D. Gene therapy. Safer and virus-free? Science 2001; 294: 1638-1642.
8. Kaiser J. Gene therapy. RAC's advice: proceed with caution. Science 2002; 298: 2113-2115.
9. Bessis N, Honiger J, Damotte D, et al. Encapsulation in hollow fibres of xenogeneic cells engineered to secrete IL-4 or IL-13 ameliorates murine collagen-induced arthritis. Clin Exp Immunol 1999; 117: 376-382.
10. Ludewig B, Ochsenbein AF, Odermatt B, et al. Immunotherapy with dendritic cells directed against tumor antigens shared with normal host cells results in severe autoimmune disease. J Exp Med 2000; 191: 795-803.
11. Walsh D, Furuzono T, Tanaka J. Preparation of porous composite implant materials by in situ polymerization of porous apatite containing epsilon-caprolactone or methyl methacrylate. Biomaterials 2001; 22: 1205-1212.
12. Dove A. Cell-based therapies go live. Nat Biotechnol 2002; 20: 339-343.
13. Yayama K, Wang C, Chao L, Chao J. Kallikrein gene delivery attenuates hypertension and cardiac hypertrophy and enhances renal function in Goldblatt hypertensive rats. Hypertension 1998; 31 1104-1110.
14. Lin KF, Chao J, Chao L. Human atrial natriuretic peptide gene delivery reduces blood pressure in hypertensive rats. Hypertension 1995; 26: 847-853.
15. Lin KF, Chao L, Chao J. Prolonged reduction of high blood pressure with human nitric oxide synthase gene delivery. Hypertension 1997; 30: 307-313.
16. Smith HW, Finkelstein N, Aliminosa L, et al. Renal clearances of substituted hippuric acid derivatives and other aromatic acids in dog and man. J Clin Invest 1945; 24: 388-404.
17. McCartney S, Cramb G. Effects of a high-salt diet on hepatic atrial natriuretic peptide receptor expression in Dahl salt-resistant and salt-sensitive rats. J Hypertens 1993; 11: 253-262.
18. Seino M, Abe K, Nushiro N, et al. The effects of atrial natriuretic peptide and amiloride on renal haemodynamics and the renal kallikrein-kinin system. J Hypertens 1988; 6: 321-327.
19. Wang C, Dobrzynski E, Chao J, Chao L. Adrenomedullin gene delivery attenuates renal damage and cardiac hypertrophy in Goldblatt hypertensive rats. Am J Physiol Renal Physiol 2001; 280: F964-F971.
20. Yla-Herttuala S, Martin JF. Cardiovascular gene therapy. Lancet 2000; 355: 213-322.
21. Chen LM, Chao L. Chao J. Adenovirus-mediated delivery of human kallistatin gene reduces blood pressure of spontaneously hypertensive rats. Hum Gene Ther 1997; 8: 341-347.
22. Tsuboniwa N, Morishita R, Hirano T, et al. Safety evaluation of hemagglutinating virus of Japan-artificial viral envelope liposomes in nonhuman primates. Hum Gene Ther 2001; 12: 469-487.
23. Data I, Shingo T, Yoshida H, et al. Grafting of encapsulated dopamine-secreting cells in Parkinson's disease: long-term primate study. Cell Transplant 2000; 9: 705-709.
24. Lanza RP, Solomon BA, Chick WL. Hollow fibers and macroencapsulation. In Methods in Cell Transplantation, Ricordi C (ed). RG Landes Company: Austin, 1995; 611-615.
25. Baras B, Benoit MA, Dupre L, et al. Single-dose mucosal immunization with biodegradable microparticles containing a Schistosoma mansoni antigen. Infect Immunol 1999; 67: 2643-2648.
26. Jeong JC, Lee J, Cho K. Effects of crystalline microstructure on drug release behavior of poly(epsilon-caprolactone) microspheres. J Control Release 2003; 92: 249-258.
27. Jameela SR, Suma N, Jayakrishnan A. Protein release from poly(epsilon-caprolactone) microspheres prepared by melt encapsulation and solvent evaporation techniques: a comparative study. J Biomater Sci Polym Ed 1997; 8: 457-466.
28. Yang YY, Chung TS, Ng NP. Morphology, drug distribution, and in vitro release profiles of biodegradable polymeric microspheres containing protein fabricated by double-emulsion solvent extraction/evaporation method. Biomaterials 2001; 22: 231-241.
29. Das GS, Rao GH, Wilson RF, Chandy T. Colchicine encapsulation within poly(ethylene glycol)-coated poly(lactic acid)/poly(epsilon-caprolactone) microspheres-controlled release studies. Drug Deliv 2000; 7: 129-138.
30. Corden TJ, Jones IA, Rudd CD, et al. Physical and biocompatibility properties of poly-epsilon-caprolactone produced using in situ polymerisation: a novel manufacturing technique for long-fibre composite materials. Biomaterials 2000; 21: 713-724.
31. Kim SY, Lee YM, Baik DJ, Kang JS. Toxic characteristics of methoxypoly(ethylene glycol)/poly(epsilon-caprolactone) nanospheres; in vitro and in vivo studies in the normal mice. Biomaterials 2003; 24: 55-63.
32. Kweon H, Yoo MK, Park IK, et al. A novel degradable polycaprolactone network for tissue engineering. Biomaterials 2003; 24: 801-808.